SCHEMBL6799338

SCHEMBL6799338

CC(=O)Nc1nc(COc2ccc([N+](=O)[O-])cc2)cs1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.70
NPC1 O15118 3/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
LMNA P02545 6/20 0.65
ALDH1A1 P00352 4/20 0.65
HTT P42858 3/20 0.65
CASP3 P42574 1/20 0.65
SENP8 Q96LD8 1/20 0.65
SENP7 Q9BQF6 1/20 0.65
SENP6 Q9GZR1 1/20 0.65
MAPT P10636 7/20 0.54
POLB P06746 1/20 0.51
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPK1 P28482 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAOB P27338 1/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083520 0.89 MAPT (0.58) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL6796683 0.83 NPC1 (0.77) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL3405939 0.83 RAB9A (0.77) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL4871628 0.83 RAB9A (1.00) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL21382353 0.82 RAB9A (0.64) RAB9ANPC1SMN1; SMN2LMNAMAPT
SCHEMBL16242472 0.81 NPC1 (0.73) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL16556647 0.80 NPC1 (0.72) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL973243 0.80 NPC1 (0.76) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL971401 0.80 NPC1 (0.72) RAB9ANPC1SMN1; SMN2LMNAALDH1A1
SCHEMBL972558 0.79 NPC1 (0.70) RAB9ANPC1SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 RAB9A 3707/4885NPC1 64/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.